Dosing Underway in Phase 1 Trial of AL101 for Potential Treatment of Parkinson’s, Other Disorders

Dosing Underway in Phase 1 Trial of AL101 for Potential Treatment of Parkinson’s, Other Disorders
Dosing has begun for healthy volunteers in a Phase 1 clinical trial of AL101, which has the potential to treat neurodegenerative disorders such as Parkinson’sAlector recently announced. The randomized, placebo-controlled trial (NCT04111666) is testing the safety, tolerability, pharmacokinetics (how the compound moves throughout the body), and pharmacodynamics (how the body interacts with the compound) of intravenously (into the vein) and ... read more
Source: Parkinson’s News TodayPublished on 2020-01-08By Forest Ray